Randomized clinical trial on safety of the natriuretic peptide ularitide as treatment of refractory cirrhotic ascites.

Ularitide in doses of 20-30 ng/kg/min did not benefit urine production and renal sodium excretion rate in patients with refractory ascites. The participants randomized to ularitide overall developed more adverse reactions than placebo. EudraCT no. 2019-002268-28.